Efficacy and safety of sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir for hepatitis C in Korea: a Phase 3b study.

"Conflicts of interest: Jeong Heo discloses receipt of grant/research support from Roche, Yuhan, and Gilead Sciences. Yoon Jun Kim discloses receipt of research grants from BTG, AstraZeneca, Gilead Sciences, Samjin, and Bayer. Jeong Won Jang discloses receipt of grants from Gilead Sciences, Yuhan Pharmaceuticals, Sysmex, and DongA ST and being a consultant and lecturer for Abbvie, Ipsen Korea, and Roche. Hyung Joon Kim discloses receipt of research grants and being an advisor, speaker, and consultant for Gilead Sciences as well as being a consultant for GSK and Roche. Sang Hoon Ahn discloses being an advisor and investigator for Gilead Sciences, Janssen Pharmaceuticals, AbbVie, Roche, Assembly Biosciences, Arbutus, Brii, Vaccitech, GSK, Inovio, Aligos, Vir Biotechnology, SL Vaxigen, GeneOne Life Science, GreenCross, Yuhan, Samil, and Ildong. Young-Suk Lim discloses receipt of research grants and being an advisory board member, speaker, and consultant for Gilead Sciences; being a speaker and consultant for Abbvie; and being a consultant for Assembly Biosciences, GSK, Olix, Roche, and Vir. Kyung Min Kwon, Vithika Suri, and Peiwen Wu are employees of Gilead Sciences and may hold stock interest in the company. Sung Wook Lee, Youn-Jae Lee, Ki Tae Yoon, Kwan-Soo Byun, Yong Jin Jung, Won Young Tak, Sook-Hyang Jeong, Byoung Kuk Jang, Byung Seok Lee, Ju-Yeon Cho, Soo Hyun Yang, Seung Woon Paik, Jung Hyun Kwon, Neung Hwa Park, Ju Hyun Kim, and In Hee Kim have no declared conflicts."

"Funding"